Improving Patient Care with AdaptDx Pro
According to a 2017 study published in JAMA Ophthalmology, 25% of age-related macular degeneration (AMD) cases go undetected—even with regular examinations using current imaging tools.ii What’s more, additional studies show 78% of AMD patients do not seek treatment until their visual acuity is irreversibly damaged in one eye.ii
We can do better for our patients!
Earlier, More Accurate Detection
Structural changes (the appearance of drusen) in the retina are not always easily discernible. They often become evident only after AMD has progressed from a subclinical state.
Being able to identify the earliest AMD biomarker with such accuracy will help improve your patients’ outcomes. It allows you to detect AMD at the subclinical stage, at least three years before drusen are visible, when action can be taken to hopefully slow disease progression.
High-Touch Patient Care
The AdaptDx Pro® also offers an optimal patient experience. The lightweight headset adapts to each patient, providing a personalized fit. A padded liner and adjustable strap enhance patient comfort. Plus, new Comfort Guard™ eyecup covers ensure a soft and clean surface for each patient.
Our friendly on-board technician, Theia™, guides patients through the test. Her personalized coaching increases the likelihood of consistent, reliable results. Powered by artificial intelligence, Theia delivers a uniform experience.
The AdaptDx Pro gives us the opportunity to change the future of macular degeneration care because it allows us to screen everyone at risk and identify macular degeneration earlier. The whole objective is to reduce the number of patients losing vision from macular degeneration.
When the Diagnosis is AMD
Once you diagnose your patient with AMD, you can determine a course of action and start monitoring the patient more frequently. Treatment recommendations for all stages of AMD include:ii
- Recommending smoking cessation programs
- Prescribing nutritional supplementation
- Discussing lifestyle modifications, such as diet and exercise
- Managing systemic diseases with the patient’s primary care physician
- Prescribing blue light protection, plus UVA and UVB sunglasses for outdoor protection
Monitoring Disease Progression
Functional testing and structural examinations may be useful for monitoring disease progression. More frequent visits increase your opportunity to detect choroidal neovascularization (CNV) before visual acuity loss. The follow-up interval may be shortened to every three or four months for patients who are progressing rapidly or are at high risk of CNV.
Improving Dark Adaptation Testing for Patients
With the AdaptDx Pro®, Dr. Ryan Powell and his staff at Insight Eyecare Specialties, Inc. are confident in their ability to provide convenient and comfortable dark adaptation testing for their patients.
Testing with AdaptDx Pro
See how your practice can use the AdaptDx Pro to help detect and monitor AMD.